Zevra Therapeutics Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Zevra Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
-2.4%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -2.4% |
| Gelecekteki Temettü Verimi | n/a |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Sep 07
The market prices ZVRA as a commercial growth story in acceleration. The numbers say something different
urgent update
Anlatı Güncellemesi • Jul 24
CHMP/EMA Refusal & Financial Risk Analysis
Zevra Therapeutics received a negative opinion (refusal) from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for Meplyffa (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC). Following the announcement, the stock reacted with an immediate ~30% decline, dropping to the $8.56 level.Seeking Alpha • Jul 23
Zevra Therapeutics: Worthy Of An Initial Holding
Summary Zevra Therapeutics surged after Miplyffa’s patent was listed in the FDA Orange Book, granting exclusivity through 2041. ZVRA achieved FY25 net sales of $87.4M, moved into profitability, retired all debt, and now holds $236.8M in cash and investments. The pipeline is focused on late-stage celiprolol for VEDS, with no clinical competition and FDA Orphan and Breakthrough Therapy designations. Trading at ~9x FY27E EPS (net of cash), ZVRA offers expansion potential, a clean balance sheet, and possible takeout appeal—supporting a small purchase. Read the full article on Seeking Alpha
Yeni Anlatı • Jul 20
Zevra Therapeutics: Galloping Through a Green Safari
From Prodrugs to a Rare Disease Powerhouse Zevra Therapeutics wasn’t always a rare disease contender. Originally known as KemPharm , the company spent years focused on prodrug technology for ADHD and pain management.
Anlatı Güncellemesi • Jul 02
ZVRA: Extended Patent Exclusivity May Support Longer NPC Revenue Runway
The analyst price target for Zevra Therapeutics has shifted from $18 to $21, with analysts pointing to extended Miplyffa patent exclusivity and updated cash flow assumptions as key drivers of their higher valuation work. Analyst Commentary on Zevra Therapeutics Recent Street research on Zevra Therapeutics has focused on how extended Miplyffa intellectual property coverage could affect long term cash flow modeling, with several firms updating their price targets and assumptions around the duration of exclusivity.
Anlatı Güncellemesi • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.Yeni Anlatı • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Anlatı Güncellemesi • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Anlatı Güncellemesi • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Anlatı Güncellemesi • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Anlatı Güncellemesi • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Anlatı Güncellemesi • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Anlatı Güncellemesi • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Anlatı Güncellemesi • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Anlatı Güncellemesi • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Anlatı Güncellemesi • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Anlatı Güncellemesi • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Anlatı Güncellemesi • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Analiz Makalesi • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Analiz Makalesi • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Analiz Makalesi • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Analiz Makalesi • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
Yeni Anlatı • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Analiz Makalesi • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Analiz Makalesi • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Analiz Makalesi • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: ZVRA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: ZVRA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Zevra Therapeutics Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (ZVRA) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.1% |
| Sektör Ortalaması (Pharmaceuticals) | 1.9% |
| Analist tahmini (ZVRA) (3 yıla kadar) | n/a |
Önemli Temettü: ZVRA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ZVRA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: ZVRA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: ZVRA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/09 12:47 |
| Gün Sonu Hisse Fiyatı | 2026/09/09 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Zevra Therapeutics, Inc. 17 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |